Parallel Advice: A False Step in March to Globalized New Drug Reviews?
This article was originally published in RPM Report
Executive Summary
Few manufacturers are taking advantage of a program under which FDA and European regulators work together to provide scientific advice to drug developers. Now the agency is wondering whether it should end the program.
You may also be interested in...
US FDA And EMA Officials Work To Boost Interest In Parallel Scientific Advice Program
Timeline and predictability concerns aren’t supported by recent data, officials argued, but questions may linger about the eligibility of products with device components.
FDA-EMA Pilot Could Further Push Global Generic Harmonization, But Will Sponsors Use It?
Regulators hope parallel scientific advice pilot for complex generics is more popular than brand program was at start; sponsors want use of foreign comparator products and tighter harmonization.
FDA-EMA Pilot Could Further Push Global Generic Harmonization, But Will Sponsors Use It?
Regulators hope parallel scientific advice pilot for complex generics is more popular than brand program was at start; sponsors want use of foreign comparator products and tighter harmonization.